CERO (CERo Therapeutics Holdings) Cash And Cash Equivalents : $3.33 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Cash And Cash Equivalents?

CERo Therapeutics Holdings's quarterly cash and cash equivalents declined from Jun. 2024 ($3.65 Mil) to Sep. 2024 ($3.38 Mil) but then stayed the same from Sep. 2024 ($3.38 Mil) to Dec. 2024 ($3.33 Mil).

CERo Therapeutics Holdings's annual cash and cash equivalents declined from Dec. 2022 ($6.82 Mil) to Dec. 2023 ($1.60 Mil) but then increased from Dec. 2023 ($1.60 Mil) to Dec. 2024 ($3.33 Mil).

CERo Therapeutics Holdings Cash And Cash Equivalents Historical Data

The historical data trend for CERo Therapeutics Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Cash And Cash Equivalents Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

19.22

6.82

1.60

3.33

CERo Therapeutics Holdings Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial						1.60	4.59	3.65	3.38	3.33

CERo Therapeutics Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CERo Therapeutics Holdings (NAS:CERO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CERo Therapeutics Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.